Background: In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and to what extent such radiotracer prototypes may be useful for targeting sst 1-5 -expressing tumors in man but, most importantly, to outline potential drawbacks and benefits associated with their use. Conclusions: This study has revealed that the native SS14 structure can indeed serve as a motif for the development of promising pansomatostatin-like radiotracers. Further peptide stabilization is required to increase in vivo stability and, consequently, to enhance in vivo delivery and tumor targeting.
]SS28 as radioligand. The ability of AT2S to stimulate sst 2 or sst 3 internalization was qualitatively analyzed by an immunofluorescence-based internalization assay using hsst 2 -or hsst 3 -expressing HEK293 cells. Furthermore, the internalization of the radioligands [ 
Results:
The new SS14-derived analogs were obtained by solid phase peptide synthesis and were easily labeled with 111 In. Both SS14 conjugates, AT1S, and its DTrp 8 counterpart, AT2S, showed a pansomatostatin affinity profile with the respective hsst [1] [2] [3] [4] [5] IC 50 values in the lower nanomolar range. In addition, AT2S behaved as an agonist for sst 2 
Background
Somatostatin-14 (SS14) is a native peptide hormone exerting a variety of physiological actions in the brain and in peripheral tissues after binding to high affinity receptors on the cell membrane of target cells [1] [2] [3] . Somatostatin receptors comprise five subtypes (sst [1] [2] [3] [4] [5] and are also found in many human tumors where they are expressed alone or in various combinations [4] [5] [6] [7] . Accordingly, they can serve as molecular targets for therapeutic interventions with somatostatin analogs. Native SS14 binds with nanomolar affinity to all five human receptor subtypes, hsst [1] [2] [3] [4] [5] , but its use for drug development is prevented by its poor in vivo stability [8] . This problem has been competently addressed by the advent of synthetic somatostatin analogs tailored to withstand enzymatic attack in vivo, such as octreotide (SMS 201-995, Sandostatin) [9] or Lanreotide (BIM 23014, Somatuline) [10] . Despite their higher potency and longer duration of action, these cyclic-octapeptide analogs have inadvertently become sst 2 -preferring and have lost most of somatostatin's affinity for the other subtypes. Yet, they have been used with success in the treatment of acromegaly and sst 2 -expressing tumors [11, 12] .
In a rather recent approach, metabolically stabilized somatostatin analogs have been functionalized with metal chelators to accommodate radiometals useful for diagnostic imaging and radionuclide therapy [13] . [ 111 In-DTPA]octreotide (OctreoScan W ) is the first approved sst 2 -avid peptide radiopharmaceutical. When administered in patients, it localizes in primary and metastatic sst 2 + -lesions, which can be efficiently visualized with the aid of an external imaging device [14] . Following OctreoScan W , several other sst 2 -seeking  radiopeptides, suitable for SPECT (  99m Tc-,  111 In-,  67 Ga-labeled), PET (  68 Ga-,  64 Cu-labeled), or radionuclide therapy ( 90 Y-or 177 Lu-labeled) have been evaluated in animal models and in patients with neuroendocrine tumors (NETs) [15] [16] [17] [18] [19] .
In all above instances, the sst 2 subtype prevails in incidence and density of expression allowing the successful application of sst 2 -preferring radioligands. However, it should be stressed that, despite the predominance of sst 2 expression in many human tumors, co-expression of sst 2 with other sst [1] [2] [3] [4] [5] subtypes is frequent enough. Thus, sst 2 and sst 5 are expressed often together in GH-secreting pituitary adenomas, and various combinations of ssts, such as sst 2 and sst 1 , are expressed in gastroenteropancreatic (GEP)-NETs.
Moreover, a number of human tumors devoid of sst 2 may instead express one or more of the other sst [1] [2] [3] [4] [5] [6, 7, 15, [20] [21] [22] . For example, ductal pancreatic carcinomas or primary hormone-sensitive prostate cancers are reported to often express sst 1 [23] [24] [25] [26] . Hence, the use of pansomatostatin-like agents will broaden the clinical indications and will increase the diagnostic/therapeutic efficacy of currently available sst 2 -preferring (radio) peptides.
SOM230 and KE108 are two multi-somatostatin receptor ligands that have been developed to improve somatostatin analog-based therapy. SOM230 has high affinity for sst [1] [2] [3] and sst 5 [27] , while KE108 has high affinity for all five sst [1] [2] [3] [4] [5] [28] . However, the absence of sst 2 internalization may turn out to be a serious disadvantage of SOM230-or KE108-based radioligands compromising their accumulation in target cells, in the most frequent cases where sst 2 expression prevails [29] [30] [31] [32] . On the other hand, well sst 2 -internalizing and multi-sst 2 -/sst 3 -/ sst 5 -binding analogs, such as DOTA-NOC [33] , will miss sst 1 -expressing tumors. Thus, a pansomatostatin affinity profile and the preservation of important pharmacological traits, especially sst 2 internalization, seem to represent an advantageous combination for enhancing the efficacy of sst 1-5 -targeting radioligands.
In this respect, the parent SS14 motif has drawn our attention despite its suboptimal metabolic stability [8] . In fact, not much is reported on the in vivo performance of radiopeptides based on SS14. In a previous study, ]SS14 showed specific and comparable to OctreoScan W accumulation in physiological sst 2 -rich tissues in mice [34] , implying that SS14-based radioligands may indeed possess sufficient in vivo stability to successfully reach their target while still able to internalize via the sst 2 .
In this study, we have coupled the universal chelator DOTA to Ala 1 of SS14 (AT1S). In this way, labeling options beyond 111 In are feasible while N-terminal capping of SS14 is also achieved, a method known to prolong the biological half-life of peptides. In the second analog, AT2S, Trp 8 was replaced by DTrp 8 to further enhance stability [35] . This modification is also reported to improve sst 2 affinity by favoring the β-turn structure for several cyclic somatostatin analogs [36] . Detailed biological characterization of the AT1S prototype and its DTrp 8 analog, AT2S, is presented herein encompassing in vitro binding affinity and functional assays in sst 1-5 -expressing cells, metabolic studies, and biodistribution of 111 In-radioligands in mice bearing sst 2 + , sst 3 + , and sst 5 + tumors. This comprehensive study will provide the basis for structural interventions on the AT1S motif towards improved pansomatostatin-like radiopeptides with advantageous key pharmacological features, such as a preserved sst 2 -internalization capacity.
Methods

Chemistry General
All chemicals were reagent grade and used without further purification. The protected chelator 2-(4,7,10-tris(2- 3 ) was purchased from Biomedica Life Sciences SA (Athens, Greece). Radiochemical HPLC analyses were performed on a Waters chromatograph (Waters, Vienna, Austria) with a 600E multi-solvent delivery system coupled to twin detection instrumentation comprising a Waters 2998 photodiode array UV detector and a Gabi γ-detector (Raytest, RSM Analytische Instrumente GmbH, Germany). Data processing and chromatographic control were conducted using the Empower software. Analyses were performed on an XTerra RP-18 (5 μm, 4.6 × 150 mm) cartridge column (Waters, Germany) and on a Symmetry Shield RP-18 (5 μm, 3.9 × 20 mm) column (Waters, Germany). Radioactivity measurements were conducted in an automated welltype γ-counter (NaI(Tl) crystal, Canberra Packard AutoGamma 5000 series model, Schwadorf, Austria) calibrated for 111 In.
Synthesis of conjugates
SPPS was performed using the standard 9-fluorenylmethoxycarbonyl (Fmoc)/tert-butyl ( -OH, respectively) were assembled on H-L-Cys(Trt)-2-Chlorotrityl resin (substitution 0.55 mmol/g). Coupling of each amino acid was performed with a threefold molar excess of Fmoc-amino acid, using 1-hydroxybenzotriazol (HOBt) (4.5-fold molar excess) and N,N′-diisopropylcarbodiimide (DIC) (3.3-fold molar excess) as activating agents, in dimethylformamide (DMF). After a period of 2.5 to 3 h, the completeness of the reaction was monitored by the standard ninhydrin test. In case of incomplete coupling, the coupling procedure was repeated prior to N α -Fmoc protecting group removal. Fmoc deprotection was performed by the addition of 25% piperidine in DMF for 15 to 25 min. Finally, DOTA-tris( t Bu)ester (threefold molar excess) was coupled at the N-terminus of the amino acid chain using HOBt (4.5-fold molar excess) and DIC (3.3-fold molar excess) in DMF. Removal of lateral chain protecting groups and cleavage from the resin was achieved by 4-h incubation in a cleavage cocktail comprising TFA:triethylaminosilane (TES):1,2-ethanedithiol:-anisole:H 2 O 93:3:2:1:1 v/v/v/v/v. The cleavage mixture was evaporated, and the free peptide conjugates were precipitated with diethyl ether and filtered. The crude peptides were dissolved in AcOH-H 2 O 4:1 to a final concentration of 2 mg/mL, and iodine (10-fold molar excess) was added in one portion. The reaction mixture was left to react for 15 to 25 min at 25°C. After the oxidation was complete, as indicated by the Ellmann test and HPLC monitoring, the reaction was quenched by diluting to twice the volume with H 2 O, and the iodine was extracted in CCl 4 . The aqueous phase was lyophilized, and the products were purified by semi-preparative HPLC on an RP-C18 support using a linear gradient from 20% to 60% MeCN (+0.1% TFA, v/v) for 40 min at a 2-mL/min flow rate. Eluted peptides were lyophilized immediately. Finally, HPLC analysis was used to monitor the purity of peptides applying two different systems: (a) HPLC system Mod.10 ÄKTA from Amersham Biosciences (Piscataway, NJ, USA) with an Alltech Nucleosil C18 column (5 μm, 4.6 × 250 mm) eluted at a flow rate of 1 mL/min with a linear gradient of 0% B to 40% B in 40 min, with A= 0.1% TFA (v/v) and B = MeCN containing 0.1% TFA (v/v) -system A; and (b) Waters chromatograph with 600E multi-solvent delivery system coupled to a Waters 2998 photodiode array UV detector using an RP-18 XTerra (5 μm, 4.6 × 150 mm) cartridge column eluted at a flow rate of 1 mL/min with a linear gradient of 0% B to 60% B in 60 min, with A = 0.1% TFA (v/v) and B = pure MeCNsystem B. Electrospray mass spectrometry (ES-MS) was conducted in order to confirm formation of the desired products.
Radiolabeling with 111
In For 111 In labeling, 111 InCl 3 in 50 mM HCl at a 370-to 740-MBq/mL activity concentration was used. Labeling was conducted by adding 10 nmol AT1S/AT2S analog per 37 to 74 MBq of 111 InCl 3 in 0.1 M sodium acetate buffer and 10 mM sodium ascorbate. Typical end pH was 4.6. Labeling was completed after incubation in a boiling water bath for 20 min [13] . Prior to HPLC quality control EDTA in 0.1 M acetate buffer was added to a final concentration of 1 mM to the labeling reaction mixture as a 'free'
111 In 3+ scavenger.
Biology Reagents
All reagents were of best grade available and were purchased from common suppliers. The sst 2 -specific antibody R2-88 was from Agnes Schönbrunn (Houston, TX, USA), and the sst 3 -specific antibody (SS-850) was purchased from Gramsch Laboratories, Schwabhausen, Germany. The secondary antibody, Alexa Fluor 488 goat anti-rabbit IgG (H + L), was from Molecular Probes, Inc.
(Eugene, OR, USA). SS14 was provided by Prof. JE Rivier (The Salk Institute, La Jolla, CA, USA).
Cell lines and animal experiments
The HEK293 cell line expressing the human T7-epitopetagged sst 2 receptor (HEK-sst 2 ) or the human sst 3 or sst 5 receptor (HEK-sst 3 , HEK-sst 5 ) were kindly provided by S. Schultz (Institute of Pharmacology and Toxicology, University Hospital, Friedrich Schiller University Jena, Germany) and cultured as previously described [38, 39] .
The rat pancreatic tumor cell line AR4-2J endogenously expressing sst 2 was kindly provided by Prof. S. Mather (St. Bartholomew's Hospital, London, UK) and cultured as previously described [37] . All culture reagents were from Gibco BRL, Life Technologies (Grand Island, NY, USA) or from Biochrom KG Seromed (Berlin, Germany). Animal experiments were carried out in compliance with European and national regulations and were approved by national authorities. For biodistribution experiments, in-house male Swiss albino mice (30 ± 5 g) were used. For experimental tumor models, in-house SCID mice of 7 weeks of age were used, and the animals were kept under aseptic conditions until biodistribution was performed.
Receptor autoradiography for hsst [1] [2] [3] [4] [5] Cell membrane pellets were prepared from human sst 1 -expressing CHO cells, sst 2 -, sst 3 -, sst 4 -expressing CCL39 cells, and sst 5 -expressing HEK293 cells and stored at −80°C. Receptor autoradiography was performed on 20-μm-thick cryostat (Microm HM 500, Walldorf, Germany) sections of the membrane pellets, mounted on microscope slides, and then stored at −20°C as previously described [39, 40] . [39] [40] [41] [42] .
Sst 2 -and sst 3 
-internalization assay
Immunofluorescence microscopy-based internalization assay for sst 2 and sst 3 was performed as previously described [38, 43] . HEK-sst 2 and HEK-sst 3 cells were grown on poly-DLys (20 μg/mL) (Sigma-Aldrich, St. Louis, MO, USA) coated 35-mm four-well plates (Cellstar, Greiner Bio-One GmbH, Frickenhausen, Germany). Cells were treated for 30 min at 37°C in growth medium with increasing concentrations ranging between 1 and 100 nM of either AT2S or SS14 (positive control). The cells were then rinsed twice with PS (100 mM phosphate buffer containing 0.15 M sucrose), fixed and permeabilized for 7 min with cold methanol (−20°C), rinsed twice with PS, and then blocked for 60 min at room temperature with PS containing 0.1% BSA. Subsequently, the cells were incubated for 60 min at room temperature with the sst 2 specific primary antibody R2-88 or the sst 3 specific primary antibody SS-850, both diluted 1:1,000 in PS and then washed 3 × 5 min with PS containing 0.1% BSA. The cells were then incubated for 60 min at room temperature in the dark with the secondary antibody Alexa Fluor 488 goat anti-rabbit IgG (H + L) diluted in PS (1:600), subsequently washed 3 × 5 min with PS containing 0.1% BSA, and embedded with PS/glycerol 1:1 and covered with a glass cover slip. The cells were imaged using a Leica DM RB immunofluorescence microscope (Leica, Deerfield, IL, USA) and an Olympus DP10 camera (Olympus Corporation, Shinjuku, Tokyo, Japan).
Radioligand internalization assay
For radioligand internalization experiments, the rsst 2 -positive cell line AR4-2J was used. Cells were grown to confluence for 48 h in six-well plates. On the day of the experiment, cells were washed twice with ice-cold internalization medium prepared with F-12-K nutrient cold 0.5% BSA PBS. Cells were then incubated twice for 5 min at ambient temperature in acid wash buffer (50 mM glycine buffer with pH 2.8, 0.1 M NaCl). The supernatant was collected (membrane-bound radioligand fraction) each time and pooled, and the cells were rinsed with 0.5% BSA PBS. Cells were lysed by treatment in 1 N NaOH, and cell radioactivity was collected (internalized radioligand fraction). Considering that total activity comprises membrane-bound plus internalized activity, the percent internalized activity versus the selected 5-, 15-, 30-, 60-, and 120-min time intervals could be calculated applying the Microsoft Excel program.
Metabolism in blood
A 150-μL bolus containing [
111 In]AT1S/[ 111 In]AT2S (11 to 22 MBq, 3 nmol total peptide) was injected in the tail vein of healthy male Swiss albino mice. The animals were kept for 5 min in cages with free access to water. They were sacrificed by cardiac puncture under ether anesthesia, and blood was withdrawn with a syringe and immediately placed in a pre-chilled EDTA-containing polypropylene vial on ice. Blood samples were centrifuged at 2,000 × g at 4°C for 10 min. The supernatant (>90% radioactivity recovered) was collected, and an equal volume of MeCN was added. The mixture was centrifuged for 10 min at 15,000 × g at 4°C. The supernatant (>90% recovery of radioactivity) was collected, and the organic solvent was removed under N 2 -flux; the residue was redissolved in physiological saline, passed through a 0.22-μm Millex-GV filter (Millipore, Milford, USA) (>90% recovery of radioactivity), and analyzed by RP-HPLC (>96% radioactivity recovered). For establishing the retention times (t R in min) of parent radiopeptides, blood samples were co-injected with the respective [ 111 In]AT1S or [
111 In]AT2S and analyzed by RP-HPLC applying the same conditions.
In vivo distribution experiments in healthy mice
For tissue distribution experiments, male Swiss albino mice were each injected with a 100-μL bolus containing [ In]AT2S (37 to 74 kBq, 10 pmol of total peptide) via the tail vein. In the in vivo receptor blockade animal group, excess Tate (50 nmol) was administered intravenously (iv) together with the radioligand. Animals were sacrificed in groups of four at 4-and 24-h time points post injection (pi). Blood and urine were immediately collected, and the organs of interest were excised and weighed; their radioactivity content was measured in an automatic gamma counter using proper standards of the injected dose. Tissue distribution data were calculated as percent injected dose per gram (%ID/g) applying a suitable algorithm.
In vivo distribution experiments in AR4-2J tumor-bearing mice
In the flanks of each of female SCID mice, inocula (150 μL) containing a suspension of 0.8 × 10 7 AR4-2J cells in PBS buffer were subcutaneously injected. Tumors of substantial size were grown within 12 days, whereupon biodistribution experiments were performed selectively for [
111 In]AT2S. Animals were injected in the tail vein with a 100-μL bolus containing [
111 In]AT2S (37 to 74 kBq, 10 pmol of total peptide); three animals were co-injected with excess Tate (50 nmol) together with the radioligand (blocked animals). Mice were sacrificed at 4 h pi, and biodistribution was studied as described above. 3 + and -hsst 5 + tumors), and biodistribution was conducted as described above.
In vivo distribution experiments in HEK293-
Statistical analysis
The in vivo data presented as mean %ID/g ± SD (n ≥ 4) were statistically analyzed with Student's t test (Prism TM 2.01, GraphPad Software, San Diego, CA, USA). Analyses were 2-tailed, and a P value < 0.05 was considered statistically significant. 
Results and discussion
Results
Synthesis of conjugates
The linear amino acid AT1S and AT2S sequences were assembled on the solid support applying the Fmoc/ t Bu methodology, and the DOTA-protected chelator was coupled at the N-terminus. The DOTA-peptide conjugates were cleaved from the solid support, and the lateral protecting groups were removed by TFA treatment. Cyclization was conducted with iodine oxidation in solution and was monitored by analytical HPLC. The cyclized products ( Figure 1) were isolated by semi-preparative HPLC and lyophilized. Product purity was assessed by analytical HPLC; ES-MS data were consistent with the expected formula ( Table 1) .
Radiolabeling
Labeling of ATIS and AT2S with 111 In (Figure 1 ) was achieved by a 20-min incubation of the analogs in acidic medium at 90°C in the presence of 111 InCl 3 , according to published protocols [13, 44] . A >96% radiometal incorporation was typically shown by HPLC analysis on an RP column; a representative radiochromatogram of [ 111 In]AT2S quality control is shown in Figure 2 .
Determination of hsst 1-5 profile
The IC 50 values of ATIS and AT2S for all five somatostatin receptor subtypes are summarized in Table 2 . Data were acquired by receptor autoradiography assays in cells selectively expressing one of the five hsst [1] [2] [3] [4] [5] [1] [2] [3] [4] [5] . However, AT1S and AT2S show a slightly lower affinity for sst 1 and sst 5 compared with the natural somatostatins, SS14 and SS28.
Sst 2 -and sst 3 -internalization assay
The ability of AT2S to stimulate sst 2 or sst 3 internalization in HEK-sst 2 and HEK-sst 3 cells was analyzed using an immunofluorescent-based internalization assay. Figure 3 illustrates that AT2S exhibits similar agonistic properties as the natural SS14 for sst 2 ( Figure 3A ) and for sst 3 ( Figure 3B ) in respect of stimulating receptor internalization.
Internalization of radioligands
The internalization properties of the radiopeptides [ 
Metabolism in blood
Both [
111 In]AT1S and [ 111 In]AT2S showed suboptimal stability in the blood stream of healthy mice. As evidenced by HPLC analysis of murine blood collected 5 min after injection of the radioligands, both analogs degraded to at least one major radiometabolite eluting with the solvent front. Traces of additional metabolites having different elution patterns for the two analogs were also observed ( Figure 5A after co-injection with radiolabeled samples not administered in mice (Figure 5 C,D, respectively) .
Biodistribution in healthy mice
Tissue distribution data of [
111 In]AT1S and [ 111 In]AT2S in healthy male Swiss albino mice for the 4-and 24-h time points are summarized as %ID/g in Figure 6A ,B, respectively. Both analogs showed a rapid clearance from blood and background tissues with minimal residual activity in pool organs. [
111 In]AT1S failed to show specific uptake in the sst 2 -rich pancreas (<0.5%ID/g at 4 h pi) in contrast with [ 111 In]AT2S, which clearly showed receptor-specific uptake in this organ (2.9%ID/g at 4 h pi versus 0.17%ID/g at 4 h pi + excess Tate) as well as in the stomach and intestines. On the other hand, kidney uptake was unfavorably higher for [
111 In]AT2S (22.9%ID/g versus 10.9%ID/g for [ 111 In]AT1S at 4 h pi). However, renal values declined over time for both analogs, reaching comparable levels at 24 h pi (6.6%ID/g for [ 111 In] AT1S and 7.6%ID/g for [
111 In]AT2S).
Biodistribution in AR4-2J tumor-bearing mice
Results of [ 111 In]AT2S tissue distribution in SCID mice bearing AR4-2J experimental tumors are included in Table 3 , as %ID/g at 1 and 4 h pi. Biodistribution data in SCID mice were consistent to the findings of healthy mice tissue distribution with specific uptake shown in the pancreas (5.13%ID/g versus 0.15%ID/g + excess Tate at 4 h pi) and the gastrointestinal tract. Uptake in the rsst 2A + tumor was shown to be specific as well, as suggested by the significantly reduced tumor values found during co-injection of excess Tate (1.82%ID/g at 4 h versus 0.21%ID/g + excess Tate at 4 h pi). Table 3 . High and specific uptake was observed in both hsst 2A + (1.49%ID/g versus 0.27%ID/g + excess DP2 at 4 h pi) and -hsst 3 + tumors (1.24%ID/g versus 0.32%ID/g + excess AT2S at 4 h pi). In the HEK293-hsst 5 + tumors, the uptake was lower (0.41%ID/g versus 0.22%ID/g + excess AT2S at 4 h pi), a finding consistent with the lower affinity of AT2S for the hsst 5 + (12 ± 2 nM) found in vitro (Table 2) .
Discussion
The success of OctreoScan W and related cyclic octapeptide sst 2 -seeking radioligands in the diagnosis and treatment of certain human tumors relies both on their high metabolic stability and on the prevalence and high density of sst 2 expression in these tumors [11] [12] [13] [14] [15] [16] [17] [18] [19] . Soon, it became apparent that sst 2 has translated into higher contrast images and to better tumoricidal responses.
On the other hand, recent studies have reported not only on the concomitant expression of at least one alternative sst [1] [2] [3] [4] [5] subtype in tumors already expressing the sst 2 , but also in tumors devoid of sst 2 expression [6, 7, 15, [20] [21] [22] [23] [24] [25] [26] . This finding provides the opportunity to use radiolabeled somatostatin analogs with an extended sst 1-5 affinity profile, which will consequently interact with more binding sites on the tumor than those limited to sst 2 . In this way, the diagnostic and therapeutic indications will be broadened to include more tumor types, while diagnostic sensitivity and therapeutic efficacy will improve. Such 'pansomatostatin-like' radioligands should possess sufficient metabolic stability to be able to reach their target after entry into the bloodstream. At the same time, their capacity to internalize in sst 2 + -cancer cells should not be compromised in order to promote accumulation in most sst [1] [2] [3] [4] [5] + -human tumors whereby sst 2 expression is dominant [27] [28] [29] [30] . It is interesting to note that pansomatostatin-like radioligands failing to internalize after binding to sst 2 in vivo indeed showed poor uptake in sst 2 + tissues in mouse models [31, 32] . On the other hand, multi-sst affine and well sst 2 -internalizing radioligands, such as radiolabeled DOTA-NOC [33] , are expected to miss sst 1 -expressing tumors in patients [23] [24] [25] [26] .
The above requirements prompted us to consider the use of native SS14 for radioligand development. It is interesting to note that a SS14-derived radiopeptide, 111 In-[DTPA,DAla 1 ,DTrp 8 ,Tyr 11 ]SS14, was previously studied in healthy mice and compared to OctreoScan W [34] . This analog displayed a pansomatostatin-like profile and showed equivalent to OctreoScan W levels of specific uptake in key target organs, such as the pituitary, the pancreas, and the adrenals, implying that SS14-based radioligands do have opportunities of good sst-targeting in vivo, including the sst 2 . No other information on similar SS14-based radiopeptides is available.
Therefore, we have decided to couple DOTA to the Nterminus of native and non-modified SS14. In this way, AT1S was first generated with the purpose to serve as a lead compound to future structurally modified pansomatostatin-like radiopeptides and as a landmark for their biological evaluation. The universal chelator DOTA has been selected over DTPA with the aim to broaden labeling options beyond 111 In to numerous other medically attractive bi-and trivalent radiometals. Coupling of DOTA on the Ala 1 primary amine of SS14 inadvertently leads to N-terminal capping of the peptide chain as well, a strategy often pursued to increase metabolic stability of peptides. In the second analog, AT2S, Trp 8 was further substituted by DTrp 8 in our AT1S motif to convey additional metabolic stability. This modification is reported to also facilitate the β-turn conformation of several cyclic somatostatin analogs leading to enriched affinity for the sst 2 [35, 36] .
Both AT1S and AT2S exhibited a pansomatostatin-like in vitro profile, binding to all five sst [1] [2] [3] [4] [5] with affinities in the lower nanomolar range. The presence of DOTA at the N-terminus has caused minor affinity losses for all subtypes, which were more pronounced for sst 1 In mice bearing AR4-2J tumors spontaneously expressing the rat sst 2 , [
111 In]AT2S showed clear specific uptake both in the experimental tumor and in the gut, including the pancreas, stomach, and intestines, as confirmed by suitable in vivo sst 2 blockade with excess of sst 2 -selective Tate. Similarly high and specific uptake was observed in HEK-hsst 2A + and HEK-sst 3 + tumors at 4 h pi, although the affinity of AT2S for the hsst 2A was slightly higher as for the hsst 3 , and AT2S showed a similar agonistic capacity in triggering the internalization of both subtypes in vitro. On the other hand, [
111 In]AT2S showed a much lower, although still specific, uptake in the HEK-hsst 5 + implants. This decrease may be attributed to its 10-fold lower affinity for hsst 5 . It should be stressed, however, that individual hsst-expression levels on transfected HEK cells may be different, thereby affecting radioligand uptake.
Conclusions
In summary, native SS14 and its DTrp 8 analog were functionalized with the universal chelator DOTA to allow for labeling with most interesting diagnostic and therapeutic radiometals. The respective AT1S prototype and its DTrp 8 derivative, AT2S, were labeled with 111 In, and several in vitro and in vivo properties of resulting (radio)ligands were investigated. According to the data obtained, both AT1S and AT2S show a pansomatostatinlike affinity profile, and AT2S displays a clear agonistic character for hsst 2 
